Romyr Dominique

Romyr Dominique

Auto-generated profile, based on publicly available information

Romyr Dominique

PMV Pharmaceuticals, Inc, Princeton, New Jersey

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2025 in Cancer Discovery
Verified
Journal Article
Open access
APAnna M. Puzio-Kuter
Anna M. Puzio-Kuter
LXLizhong Xu
Lizhong Xu
MMMary Kate McBrayer
Mary Kate McBrayer
RDRomyr Dominique
Romyr Dominique
HLHongju H. Li
Hongju H. Li
MPMasha V. Poyurovsky
Masha V. Poyurovsky
Restoration of the tumor suppressor function of tumor-associated p53 mutants, including the Y220C substitution, has posed a significant challenge for therapeutic discovery. In this study, we describe rezatapopt (PC14586), part of a series of compounds designed to reactivate the p53 Y220C mutant. These compounds restore p53 tumor suppressor function by correcting its conformation and enabling it to bind DNA and activate downstream target genes, thus inducing antiproliferative changes in tumor cells. Our findings are supported by biochemical and structural analysis, in vitro and in vivo transcriptomics, and functional data, revealing the recovery of multiple aspects of the wild-type p53 program. These compounds demonstrate potent antitumor activity in preclinical models as single agents and in combination with immunotherapy. Currently, rezatapopt is being evaluated in a registrational phase II clinical trial for patients with advanced solid tumors harboring the TP53 Y220C mutation. Significance: Rezatapopt is a clinical-stage compound that offers a promising treatment option for TP53-mutant cancers. This study details the characterization of rezatapopt and its related compounds, which can reinstate the tumor suppressor activity of the p53 Y220C mutant. These results emphasize the potential for targeting p53 mutations in cancer therapy.

3 June 2025
Verified
Other
Open access
PDF file
APAnna M. Puzio-Kuter
Anna M. Puzio-Kuter
LXLizhong Xu
Lizhong Xu
MMMary Kate McBrayer
Mary Kate McBrayer
RDRomyr Dominique
Romyr Dominique
HLHongju H. Li
Hongju H. Li
MPMasha V. Poyurovsky
Masha V. Poyurovsky
Supplementary Figure S1. Functional Characterization of p53-Y220C Reactivator Compounds. Supplementary Figure S2. Reactivator Compounds are Active Only in p53-Y220C Cell Lines. Supplementary Figure S3. Selective Restoration of Wild-Type (WT) p53 Transcriptional Responses by PC14586 in Cells. Supplementary Figure S4. In Vivo Administration of PC14586 Leads to Tumor Growth Inhibition of Activation of Downstream Biomarkers. Supplementary Figure S5. PC14586 Restored Multiple Facets of Dynamic Wild-Type (WT) p53 Transcriptional Responses in Vivo. Supplementary Figure S6. PC14586 Administration in Vivo Led to Regulation of Genes Specific for Immune and Inflammatory Responses. Supplementary Figure S7. Clinical Timelines of Two Patients with Advanced Solid Tumors Harboring a TP53 Y220C Mutation Receiving Rezatapopt.

3 June 2025
Verified
Other
Open access
APAnna M. Puzio-Kuter
Anna M. Puzio-Kuter
LXLizhong Xu
Lizhong Xu
MMMary Kate McBrayer
Mary Kate McBrayer
RDRomyr Dominique
Romyr Dominique
HLHongju H. Li
Hongju H. Li
MPMasha V. Poyurovsky
Masha V. Poyurovsky
Selective restoration of WT p53 transcriptional responses by PC14586 in cells. A, Quantification of CDKN1A (p21) and MDM2 mRNA by qRT-PCR in p53-Y220C, other p53 hotspot mutants, p53 WT, and p53 KO cell lysates following 5 hours of treatment with rezatapopt (PC14586). Data for the top four cell lines were representative results of three biological repeats, data for other cell lines were from two biological repeats, and graphs were plotted as mean ± SD. A.U., arbitrary unit. B, Scatter plots showing expression levels of genes involved in the p53 signaling pathway in cells following treatment with rezatapopt (PC14586). RNA samples extracted from p53-Y220C–expressing cells (NUGC-3), p53 KO cells (NUGC-3 KO) treated with rezatapopt (PC14586; 5 µmol/L, 16 hours), and NUGC-3 KO_p53i cells induced with doxycycline (50 ng/mL, 12.5 hours) were profiled by the Qiagen RT2 p53 pathway qRT-PCR panel. Scales are in log10 (relative expression to housekeeping genes; n = 3). C, Scatter plots of log2 (transcripts per million + 0.01) and volcano plots of −log10 (FDR) versus log2 (fold change) from RNA-seq analysis of expressed genes from p53-Y220C and p53 KO cell lines following DMSO and rezatapopt (PC14586; 5 µmol/L) treatment (16 hours). Genes enriched in gene sets of Fischer direct p53 targets (upregulated), Fischer DREAM Targets (downregulated), DEGs excluding the above-enriched genes (upregulated and downregulated), and non-DEGs were sequentially overlaid as indicated. D, Top enriched gene sets from GSEA of the Molecular Signatures Database C2 collection curated gene sets in the indicated RNA-seq data (NUGC-3 treated with 5 µmol/L PC14586 versus DMSO for 16 hours) from DEGs (Walden stat preranked). The number of overlapping genes from the upregulated DEGs enriched in both the Fischer direct p53 targets gene set, and each listed gene set was divided by the total number of genes in each listed gene set and then multiplied by 100 to obtain the overlap with Fischer_Direct_p53_Targets (%). Overlap with Fischer DREAM targets (%) was calculated in a similar manner, except using the downregulated DEGs. To calculate enrichment (%), the number of genes from the DEGs with the indicated direction of regulation enriched in each gene set was divided by the total number of genes in each listed gene set and multiplied by 100. Normalized enrichment scores (NES) and percentages (%) were plotted on the upper and lower x-axes. All gene sets shown had enrichment of FDR q value (q) <0.001. Note that the names of gene sets were shortened. See Supplementary File S11 for details. E, Examples of the GSEA enrichment plots from D. F, Schematic representation of p53 in the transcriptional repression of cell-cycle genes via retinoblastoma-E2F and DREAM complexes. CDK, cyclin-dependent kinase; RBL, retinoblastoma-like proteins p107 (RBL1) and p130 (RBL2).

3 June 2025
Verified
Other
Open access
APAnna M. Puzio-Kuter
Anna M. Puzio-Kuter
LXLizhong Xu
Lizhong Xu
MMMary Kate McBrayer
Mary Kate McBrayer
RDRomyr Dominique
Romyr Dominique
HLHongju H. Li
Hongju H. Li
MPMasha V. Poyurovsky
Masha V. Poyurovsky
P53 pathway profiling analysis in NUGC-3 KO_p53i cells induced with doxycycline (50 ng/ml) vs. PBS control (12.5 h).

3 June 2025
Verified
Other
Open access
APAnna M. Puzio-Kuter
Anna M. Puzio-Kuter
LXLizhong Xu
Lizhong Xu
MMMary Kate McBrayer
Mary Kate McBrayer
RDRomyr Dominique
Romyr Dominique
HLHongju H. Li
Hongju H. Li
MPMasha V. Poyurovsky
Masha V. Poyurovsky
GSEA analysis using MSigDB Hallmark gene sets collection (H) for all detected genes demonstrated the regulation of genes for immune and inflammatory response in vivo in NUGC-3 xenograft tumors following 8 h of treatment with 100 mg/kg PC14586.

3 June 2025
Verified
Other
Open access
APAnna M. Puzio-Kuter
Anna M. Puzio-Kuter
LXLizhong Xu
Lizhong Xu
MMMary Kate McBrayer
Mary Kate McBrayer
RDRomyr Dominique
Romyr Dominique
HLHongju H. Li
Hongju H. Li
MPMasha V. Poyurovsky
Masha V. Poyurovsky
Pharmacologic activation of WT p53 inhibited tumor growth and induced immunologic cell changes in tumors. A, Average tumor volume (mm3; left), AUC analysis of tumor growth (middle), and percentage of body weight change (right) in C57Bl/6 mice bearing subcutaneous MT373 tumors treated with vehicle (V) or PC14374 at 150 or 300 mg/kg (2Q7D: two doses on day 1 only on a weekly dosing cycle). n =10/group. Data shown are mean ± SEM. Percentage of TGI (% TGI) or tumor regression is relative to tumor volume at study start. Statistical significance relative to the vehicle was determined using one-way ANOVA with Dunnett’s multiple comparisons tests (adjusted P value: **** <0.0001). B and C, Six days after inoculation with MT373 cells, mice were administered PC14374 orally at 150 or 300 mg/kg (2Q7D × 2 or 2Q7D × 3: two doses on day 1 only of a weekly dosing cycle for 2 or 3 weeks, respectively). B, Tumors were harvested 72 hours after last dose to analyze tumor-infiltrating lymphocytes by flow cytometry. Percentage of cell population change is normalized to CD45+ cells. Vehicle, n = 3/group; PC14374, n = 4/group. Error bars show SEM. Statistical significance relative to the vehicle was determined using one-way ANOVA with Dunnett’s multiple comparisons tests (adjusted P value: * ≤0.01; *** ≤0.001; **** ≤0.0001). C, Tumors harvested 72 hours after last dose were analyzed on the NanoString IO 360 panel for gene expression. Box plots represent fold change in the signature scores and the raw P value for the comparison between treatments for each cell signature (*, P ≤0.01; **, P ≤0.001). Vehicle control is treated as the baseline of the comparison. Vehicle, n = 3/group; PC14374, n = 4/group. Error bars show SEM. D, Mice bearing MT373 tumors were administered 75 mg/kg or 150 mg/kg PC14374 (2Q7D: two doses on day 1 only of a weekly dosing cycle), 200 µg anti–PD-1 (Q3D: dose every three days), or a combination of PC14374 and anti–PD-1 starting on day 6 after cell implantation. Tumor volume (mm3) measurements started on day 1 of dosing. Kaplan–Meier curves are shown as percentage of survival with n = 10/group. The dashed vertical line represents dosing discontinuation at day 102. E, Mice bearing MT373 tumors were administered 150 mg/kg of PC14374 (2Q7D), 200 µg of anti–PD-1 (Bio X Cell Clone RMPI-14; Q3D), or 250 µg of anti-CD8 (Bio X Cell Clone 2.43) as single agents or in combination starting on day 6 after cell implantation. Groups dosed with anti-CD8 were pretreated 3 days prior to the study start. Tumor volume (mm3) measurements started on day 1 of dosing. Kaplan–Meier curves are shown as percentage of survival with n = 10/group. The dashed vertical line represents dosing discontinuation on day 19. Statistical significance across all groups was determined using the log-rank (Mantel–Cox) test.